Allied Healthcare Products Competitors

Allied Healthcare Products (NASDAQ:AHPI) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Allied Healthcare Products and Intuitive Surgical, as provided by MarketBeat.com.

Intuitive Surgical has a consensus price target of $750.9444, indicating a potential downside of 7.12%. Given Intuitive Surgical's higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than Allied Healthcare Products.

Insider and Institutional Ownership

9.5% of Allied Healthcare Products shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 23.8% of Allied Healthcare Products shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Allied Healthcare Products has a beta of -5.06, meaning that its stock price is 606% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Allied Healthcare Products and Intuitive Surgical's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Allied Healthcare Products and Intuitive Surgical's gross revenue, earnings per share and valuation.

Intuitive Surgical has higher revenue and earnings than Allied Healthcare Products.

Summary

Intuitive Surgical beats Allied Healthcare Products on 10 of the 11 factors compared between the two stocks.

Allied Healthcare Products (NASDAQ:AHPI) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Allied Healthcare Products and Edwards Lifesciences, as provided by MarketBeat.com.

Edwards Lifesciences has a consensus price target of $91.1569, indicating a potential upside of 3.35%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Allied Healthcare Products.

Insider and Institutional Ownership

9.5% of Allied Healthcare Products shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 23.8% of Allied Healthcare Products shares are held by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Allied Healthcare Products has a beta of -5.06, meaning that its stock price is 606% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Allied Healthcare Products and Edwards Lifesciences' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Allied Healthcare Products and Edwards Lifesciences' gross revenue, earnings per share and valuation.

Edwards Lifesciences has higher revenue and earnings than Allied Healthcare Products.

Summary

Edwards Lifesciences beats Allied Healthcare Products on 10 of the 11 factors compared between the two stocks.

Allied Healthcare Products (NASDAQ:AHPI) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Allied Healthcare Products and Align Technology, as provided by MarketBeat.com.

Align Technology has a consensus price target of $502.1667, indicating a potential downside of 16.36%. Given Align Technology's higher probable upside, analysts plainly believe Align Technology is more favorable than Allied Healthcare Products.

Insider and Institutional Ownership

9.5% of Allied Healthcare Products shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 23.8% of Allied Healthcare Products shares are held by insiders. Comparatively, 1.2% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Allied Healthcare Products has a beta of -5.06, meaning that its stock price is 606% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Profitability

This table compares Allied Healthcare Products and Align Technology's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Allied Healthcare Products and Align Technology's gross revenue, earnings per share and valuation.

Align Technology has higher revenue and earnings than Allied Healthcare Products.

Summary

Align Technology beats Allied Healthcare Products on 10 of the 11 factors compared between the two stocks.

Allied Healthcare Products (NASDAQ:AHPI) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Risk & Volatility

Allied Healthcare Products has a beta of -5.06, meaning that its stock price is 606% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Allied Healthcare Products and Zimmer Biomet, as provided by MarketBeat.com.

Zimmer Biomet has a consensus price target of $167.8636, indicating a potential downside of 1.64%. Given Zimmer Biomet's higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Allied Healthcare Products.

Insider and Institutional Ownership

9.5% of Allied Healthcare Products shares are held by institutional investors. Comparatively, 87.2% of Zimmer Biomet shares are held by institutional investors. 23.8% of Allied Healthcare Products shares are held by insiders. Comparatively, 0.4% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Allied Healthcare Products and Zimmer Biomet's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Allied Healthcare Products and Zimmer Biomet's gross revenue, earnings per share and valuation.

Zimmer Biomet has higher revenue and earnings than Allied Healthcare Products.

Summary

Zimmer Biomet beats Allied Healthcare Products on 11 of the 12 factors compared between the two stocks.

Allied Healthcare Products (NASDAQ:AHPI) and STERIS (NYSE:STE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility & Risk

Allied Healthcare Products has a beta of -5.06, meaning that its share price is 606% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Allied Healthcare Products and STERIS, as provided by MarketBeat.

STERIS has a consensus price target of $214.25, indicating a potential upside of 3.76%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than Allied Healthcare Products.

Insider & Institutional Ownership

9.5% of Allied Healthcare Products shares are owned by institutional investors. Comparatively, 90.0% of STERIS shares are owned by institutional investors. 23.8% of Allied Healthcare Products shares are owned by insiders. Comparatively, 1.2% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Allied Healthcare Products and STERIS's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Allied Healthcare Products and STERIS's gross revenue, earnings per share and valuation.

STERIS has higher revenue and earnings than Allied Healthcare Products.

Summary

STERIS beats Allied Healthcare Products on 10 of the 11 factors compared between the two stocks.

Allied Healthcare Products (NASDAQ:AHPI) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility & Risk

Allied Healthcare Products has a beta of -5.06, meaning that its share price is 606% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Allied Healthcare Products and Smith & Nephew, as provided by MarketBeat.

Smith & Nephew has a consensus price target of $47.1667, indicating a potential upside of 17.74%. Given Smith & Nephew's higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Allied Healthcare Products.

Insider & Institutional Ownership

9.5% of Allied Healthcare Products shares are owned by institutional investors. Comparatively, 8.9% of Smith & Nephew shares are owned by institutional investors. 23.8% of Allied Healthcare Products shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Allied Healthcare Products and Smith & Nephew's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Allied Healthcare Products and Smith & Nephew's gross revenue, earnings per share and valuation.

Smith & Nephew has higher revenue and earnings than Allied Healthcare Products.

Summary

Smith & Nephew beats Allied Healthcare Products on 9 of the 11 factors compared between the two stocks.